Ocular Therapeutix (OCUL) Capital Expenditures (2013 - 2026)
Ocular Therapeutix's quarterly Capital Expenditures came in at $1.3 million in Q1 2026, down 31.35% year-on-year from $1.9 million in Q1 2025, and up 116.59% quarter-over-quarter from -$8.0 million in Q4 2025.
Ocular Therapeutix has reported Capital Expenditures for 14 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 31.35% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $568000.0 (down 68.43% YoY), and the FY2025 full-year result was $1.2 million, up 870.25% from the prior year.
- Capital Expenditures for Q1 2026 stood at $1.3 million, up from -$8.0 million in the prior quarter.
- The five-year high for Capital Expenditures was $6.0 million in Q3 2025, with the low at -$8.0 million in Q4 2025.
- Average Capital Expenditures over 5 years is $373705.9, with a median of $276000.0 recorded in 2022.
- Year-over-year, Capital Expenditures jumped 15335.48% in 2023 and plunged 17871.11% in 2025.
- Tracing OCUL's Capital Expenditures over 5 years: stood at $3.2 million in 2022, then sank by 273.32% to -$5.6 million in 2023, then surged by 100.8% to $45000.0 in 2024, then sank by 17871.11% to -$8.0 million in 2025, then soared by 116.59% to $1.3 million in 2026.
- The last three Capital Expenditures figures came in at $1.3 million (Q1 2026), -$8.0 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.33 Mn |
| Mar 31, 2026 | 1.33 Mn |
| Dec 31, 2025 | -8.00 Mn |
| Dec 31, 2025 | -8.00 Mn |
| Sep 30, 2025 | 5.99 Mn |
| Sep 30, 2025 | 5.99 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 45,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Sep 30, 2024 | -921,000.00 |
| Sep 30, 2024 | -921,000.00 |
| Jun 30, 2024 | 742,000.00 |
| Jun 30, 2024 | 742,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Dec 31, 2023 | -5.61 Mn |
| Dec 31, 2023 | -5.61 Mn |
| Sep 30, 2023 | 259,000.00 |
| Sep 30, 2023 | 259,000.00 |
| Jun 30, 2023 | 4.72 Mn |
| Jun 30, 2023 | 4.72 Mn |
| Mar 31, 2023 | 646,000.00 |
| Mar 31, 2023 | 646,000.00 |
| Dec 31, 2022 | 3.24 Mn |
| Dec 31, 2022 | 3.24 Mn |
| Sep 30, 2022 | 232,000.00 |
| Sep 30, 2022 | 232,000.00 |
| Jun 30, 2022 | -31,000.00 |
| Jun 30, 2022 | -31,000.00 |
| Mar 31, 2022 | 276,000.00 |
| Mar 31, 2022 | 276,000.00 |
| Dec 31, 2021 | 631,000.00 |
| Dec 31, 2021 | 631,000.00 |
| Sep 30, 2021 | 555,000.00 |
| Sep 30, 2021 | 555,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 20,000.00 |
| Dec 31, 2020 | 20,000.00 |
| Sep 30, 2020 | -303,000.00 |
| Sep 30, 2020 | -303,000.00 |
| Jun 30, 2020 | 125,000.00 |
| Jun 30, 2020 | 125,000.00 |
| Mar 31, 2020 | 249,000.00 |
| Mar 31, 2020 | 249,000.00 |
| Dec 31, 2019 | -250,000.00 |
| Dec 31, 2019 | -250,000.00 |
| Sep 30, 2019 | -754,000.00 |
| Sep 30, 2019 | -754,000.00 |
| Jun 30, 2019 | 1.04 Mn |
| Jun 30, 2019 | 1.04 Mn |
| Mar 31, 2019 | 176,000.00 |
| Mar 31, 2019 | 176,000.00 |
| Dec 31, 2018 | -1.26 Mn |
| Dec 31, 2018 | -1.26 Mn |
| Sep 30, 2018 | 1.32 Mn |
| Sep 30, 2018 | 1.32 Mn |
| Jun 30, 2018 | -292,000.00 |
| Jun 30, 2018 | -292,000.00 |
| Mar 31, 2018 | 381,000.00 |
| Mar 31, 2018 | 381,000.00 |
| Dec 31, 2017 | 224,000.00 |
| Dec 31, 2017 | 224,000.00 |
| Sep 30, 2017 | -955,000.00 |
| Sep 30, 2017 | -955,000.00 |
| Jun 30, 2017 | -385,000.00 |
| Jun 30, 2017 | -385,000.00 |
| Mar 31, 2017 | 1.65 Mn |
| Mar 31, 2017 | 1.65 Mn |
| Dec 31, 2016 | 680,000.00 |
| Dec 31, 2016 | 680,000.00 |
| Sep 30, 2016 | 1.05 Mn |
| Sep 30, 2016 | 1.05 Mn |
| Jun 30, 2016 | 79,000.00 |
| Jun 30, 2016 | 79,000.00 |
| Mar 31, 2016 | 109,000.00 |
| Mar 31, 2016 | 109,000.00 |
| Dec 31, 2015 | 473,000.00 |
| Dec 31, 2015 | 473,000.00 |
| Sep 30, 2015 | 76,000.00 |
| Sep 30, 2015 | 76,000.00 |
| Jun 30, 2015 | 875,000.00 |
| Jun 30, 2015 | 875,000.00 |
| Mar 31, 2015 | 354,000.00 |
| Mar 31, 2015 | 354,000.00 |
| Dec 31, 2014 | 129,000.00 |
| Dec 31, 2014 | 129,000.00 |
| Sep 30, 2014 | -47,000.00 |
| Sep 30, 2014 | -47,000.00 |
| Jun 30, 2014 | -210,000.00 |
| Jun 30, 2014 | -210,000.00 |
| Mar 31, 2014 | 297,000.00 |
| Mar 31, 2014 | 297,000.00 |
| Dec 31, 2013 | -45,000.00 |
| Dec 31, 2013 | -45,000.00 |
| Sep 30, 2013 | 133,000.00 |
| Sep 30, 2013 | 133,000.00 |